scholarly journals Pre-operative direct and inverse clinical characteristic variations by age do not resolve up to 24 months following open roux-en-y gastric bypass

2021 ◽  
Vol 11 (5) ◽  
pp. 146-153
Author(s):  
Ajay Menon ◽  
David Kelter ◽  
Gus J Slotman

Background: Today open Roux-en-Y gastric bypass (ORYGB) is reserved for abdomens too complex or obesity too severe for laparoscopic surgery. However, outcomes by age in ORYGB are unknown. Objective: Identify variation by age in ORYGB patients. Setting: Independent database. Methods: 5389 ORYGB BOLD patients was analyzed retrospectively by age: <30 (591), 30-40 (1252), 40-50 (1527), 50-60 (1388), 60-70 (592) and >70 (39). Statistics: ANOVA/general linear model. Results: Baseline female/male (p<0.01), weight, BMI, African-American, Hispanic, Medicaid, Private insurance, self-pay (p<0.0001), PCOS, PTC (n=10) varied inversely with age. Medicare, CHF, HTN, angina, LEE, PVD, IHD, dyslipidemia, OHS, diabetes, gout, IFS, and unemployment varied directly. Caucasian, Asian, Other race, DVT/PE, hernia, cholelithiasis, GERD, panniculitis, liver disease, SUI, MSP, fibromyalgia, alcohol and tobacco abuse, depression, PI, MHD (n=17) vary non-linearly. At 12 months, in spite of equal BMI by age, CHF, HTN, angina, PVD, dyslipidemia, cholelithiasis, SUI, diabetes, gout, IFS (n=10) varied directly. PCOS and PTC varied inversely, and LEE, OSA, hernia, MSP, tobacco abuse, depression, MHD varied non-linearly. 24 months CHF, HTN, angina, dyslipidemia, diabetes, IFS, and MSP vary directly. PTC and tobacco abuse varied inversely. LEE, OSA, PHTN, hernia, PCOS, and tobacco abuse varied non-linearly. Conclusions: ORYGB patients vary dramatically by decade of age. Pre-operatively 10 co-morbidities varied inversely, 13 directly, and 17 non-linearly by age. In spite of equal BMI by age at 24 months, important co-morbidities CHF, HTN, angina, dyslipidemia, diabetes varied directly, tobacco inversely, and OSA non-linearly. This advance clinical knowledge of age variation can aid ORYGB management

2014 ◽  
Vol 207 (6) ◽  
pp. 942-948 ◽  
Author(s):  
Jon S. Thompson ◽  
Rebecca A. Weseman ◽  
Fedja A. Rochling ◽  
Wendy J. Grant ◽  
Jean F. Botha ◽  
...  

2021 ◽  
Author(s):  
Miller Barreto de Brito e Silva ◽  
Francisco Tustumi ◽  
Antonio Afonso de Miranda Neto ◽  
Anna Carolina Batista Dantas ◽  
Marco Aurélio Santo ◽  
...  

2005 ◽  
Vol 13 (7) ◽  
pp. 1180-1186 ◽  
Author(s):  
Jeanne M. Clark ◽  
Amir R. A. Alkhuraishi ◽  
Steven F. Solga ◽  
Patricia Alli ◽  
Anna Mae Diehl ◽  
...  

2017 ◽  
Vol 266 (5) ◽  
pp. 738-745 ◽  
Author(s):  
Piotr Kalinowski ◽  
Rafał Paluszkiewicz ◽  
Bogna Ziarkiewicz-Wróblewska ◽  
Tadeusz Wróblewski ◽  
Piotr Remiszewski ◽  
...  

2011 ◽  
Vol 140 (5) ◽  
pp. S-1022
Author(s):  
Jon Thompson ◽  
Rebecca A. Weseman ◽  
Fedja A. Rochling ◽  
Wendy J. Grant ◽  
Jean Botha ◽  
...  

2021 ◽  
Vol 10 (17) ◽  
pp. 3783
Author(s):  
Julie Steen Pedersen ◽  
Marte Opseth Rygg ◽  
Reza Rafiolsadat Serizawa ◽  
Viggo Bjerregaard Kristiansen ◽  
Nicolai J. Wewer Albrechtsen ◽  
...  

Roux-en-Y gastric bypass (RYGB) improves, and can sometimes resolve, non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) but data based on histological assessment for the efficacy of sleeve gastrectomy (SG) in resolving NAFLD are sparse. Consequently, we aimed to compare the efficacy of RYGB vs. SG on NAFLD 12 months after surgery. In a prospective cohort study, 40 patients with obesity underwent bariatric surgery (16 RYGB and 24 SG). During surgery, a liver biopsy was taken and repeated 12 months later. NAFLD severity was evaluated using the NAFLD Activity Score (NAS) and Kleiner Fibrosis score. RYGB and SG patients were comparable at baseline. Mean (standard deviation, SD) NAS was 3.3 (0.9) in RYGB and 3.1 (1.4) in SG (p = 0.560) with similar degrees of steatosis, inflammation, and ballooning. Two RYGB patients, and six SG patients, had NASH (p = 0.439). Twelve months after surgery, NAS was significantly and comparably (p = 0.241) reduced in both RYGB (−3.00 (95% CI −3.79–−2.21), p < 0.001) and SG (−2.25 (95% CI −2.92–−1.59), p < 0.001) patients. RYGB patients had significantly more reduced (p = 0.007) liver steatosis (−0.91 (95% CI −1.47–−1.2) than SG patients (−0.33 (95% CI −0.54–−0.13) and greater improvement in the plasma lipid profile. Fibrosis declined non-significantly. NASH was resolved in seven of eight patients without a worsening of their fibrosis. RYGB and SG have similar beneficial effects on NAS and NASH without the worsening of fibrosis. RYGB is associated with a more pronounced reduction in liver steatosis.


Sign in / Sign up

Export Citation Format

Share Document